Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Neuromedin U is regulated by the metastasis suppressor RhoGDI2 and is a novel promoter of tumor formation, lung metastasis and cancer cachexia

Oncogene volume 26, pages 765–773 (2007)Cite this article

Abstract

Most deaths from urinary bladder cancer are owing to metastatic disease. A reduction in Rho GDP Dissociation Inhibitor 2 (RhoGDI2) protein has been associated with increased risk of metastasis in patients with locally advanced bladder cancer, whereas in animal models, RhoGDI2 reconstitution in cells without expression results in lung metastasis suppression. Recently, we noted an inverse correlation between tumor RhoGDI2 and Neuromedin U (NMU) expression, suggesting that NMU might be a target of the lung metastasis suppressor effect of RhoGDI2. Here we evaluated whether NMU is regulated by RhoGDI2 and is functionally important in tumor progression. We used small interfering RNA knockdown of endogenous RhoGDI2 in poorly tumorigenic and non-metastatic human bladder cancer T24 cells and observed increased NMU RNA expression. Although NMU overexpression did not increase the monolayer growth of T24 or related T24T poorly metastatic human bladder cancer cells, it did augment anchorage-independent growth for the latter. Overexpression of NMU in T24 and T24T cells significantly promoted tumor formation of both cell lines in nude mice, but did not alter the growth rate of established tumors. Furthermore, NMU-overexpressing xenografts were associated with lower animal body weight than control tumors, indicating a possible role of NMU in cancer cachexia. NMU overexpression in T24T cells significantly enhanced their lung metastatic ability. Bioluminescent in vivo imaging revealed that lung metastases in T24T grew faster than the same tumors in the subcutaneous microenvironment. In conclusion, NMU is a RhoGDI2-regulated gene that appears important for tumorigenicity, lung metastasis and cancer cachexia, and thus a promising therapeutic target in cancer.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  • Alevizos I, Mahadevappa M, Zhang X, Ohyama H, Kohno Y, Posner M et al. (2001). Oral cancer in vivo gene expression profiling assisted by laser capture microdissection and microarray analysis. Oncogene 20: 6196–6204.

    Article  CAS  PubMed  Google Scholar 

  • Brighton PJ, Szekeres PG, Willars GB . (2004). Neuromedin U and its receptors: structure, function, and physiological roles. Pharmacol Rev 56: 231–248.

    Article  CAS  PubMed  Google Scholar 

  • Cameron MD, Schmidt EE, Kerkvliet N, Nadkarni KV, Morris VL, Groom AC et al. (2000). Temporal progression of metastasis in lung: cell survival, dormancy, and location dependence of metastatic inefficiency. Cancer Res 60: 2541–2546.

    CAS  PubMed  Google Scholar 

  • Cao CQ, Yu XH, Dray A, Filosa A, Perkins MN . (2003). A pro-nociceptive role of neuromedin U in adult mice. Pain 104: 609–616.

    Article  CAS  PubMed  Google Scholar 

  • Chan IS, Zhang Z . (1999). Test-based exact confidence intervals for the difference of two binomial proportions. Biometrics 55: 1202–1209.

    Article  CAS  PubMed  Google Scholar 

  • Chung LW, Baseman A, Assikis V, Zhau HE . (2005). Molecular insights into prostate cancer progression: the missing link of tumor microenvironment. J Urol 173: 10–20.

    Article  PubMed  Google Scholar 

  • Clark EA, Golub TR, Lander ES, Hynes RO . (2000). Genomic analysis of metastasis reveals an essential role for RhoC. Nature 406: 532–535.

    Article  CAS  PubMed  Google Scholar 

  • Euer NI, Kaul S, Deissler H, Mobus VJ, Zeillinger R, Weidle UH . (2005). Identification of L1CAM, Jagged2 and neuromedin U as ovarian cancer-associated antigens. Oncol Rep 13: 375–387.

    CAS  PubMed  Google Scholar 

  • Fidler IJ, Ellis LM . (1994). The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 79: 185–188.

    Article  CAS  PubMed  Google Scholar 

  • Gildea JJ, Golden WL, Harding MA, Theodorescu D . (2000). Genetic and phenotypic changes associated with the acquisition of tumorigenicity in human bladder cancer. Genes Chromosomes Cancer 27: 252–263.

    Article  CAS  PubMed  Google Scholar 

  • Gildea JJ, Seraj MJ, Oxford G, Harding MA, Hampton GM, Moskaluk CA et al. (2002). RhoGDI2 is an invasion and metastasis suppressor gene in human cancer. Cancer Res 62: 6418–6423.

    CAS  PubMed  Google Scholar 

  • Hanada R, Teranishi H, Pearson JT, Kurokawa M, Hosoda H, Fukushima N et al. (2004). Neuromedin U has a novel anorexigenic effect independent of the leptin signaling pathway. Nat Med 10: 1067–1073.

    Article  CAS  PubMed  Google Scholar 

  • Harding MA, Arden KC, Gildea JW, Gildea JJ, Perlman EJ, Viars C et al. (2002). Functional genomic comparison of lineage-related human bladder cancer cell lines with differing tumorigenic and metastatic potentials by spectral karyotyping, comparative genomic hybridization, and a novel method of positional expression profiling. Cancer Res 62: 6981–6989.

    CAS  PubMed  Google Scholar 

  • Howard AD, Wang R, Pong SS, Mellin TN, Strack A, Guan XM et al. (2000). Identification of receptors for neuromedin U and its role in feeding. Nature 406: 70–74.

    Article  CAS  PubMed  Google Scholar 

  • Ida T, Mori K, Miyazato M, Egi Y, Abe S, Nakahara K et al. (2005). Neuromedin S is a novel anorexigenic hormone. Endocrinology 146: 4217–4223.

    Article  CAS  PubMed  Google Scholar 

  • Im JH, Fu W, Wang H, Bhatia SK, Hammer DA, Kowalska MA et al. (2004). Coagulation facilitates tumor cell spreading in the pulmonary vasculature during early metastatic colony formation. Cancer Res 64: 8613–8619.

    Article  CAS  PubMed  Google Scholar 

  • Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ . (2003). Cancer statistics, 2003. CA Cancer J Clin 53: 5–26.

    Article  PubMed  Google Scholar 

  • Jenkins DE, Yu SF, Hornig YS, Purchio T, Contag PR . (2003). In vivo monitoring of tumor relapse and metastasis using bioluminescent PC-3M-luc-C6 cells in murine models of human prostate cancer. Clin Exp Metast 20: 745–756.

    Article  Google Scholar 

  • Johnson EN, Appelbaum ER, Carpenter DC, Cox RF, Disa J, Foley JJ et al. (2004). Neuromedin U elicits cytokine release in murine Th2-type T cell clone D10.G4.1. J Immunol 173: 7230–7238.

    Article  CAS  PubMed  Google Scholar 

  • Kamai T, Kawakami S, Koga F, Arai G, Takagi K, Arai K et al. (2003a). RhoA is associated with invasion and lymph node metastasis in upper urinary tract cancer. BJU Int 91: 234–238.

    Article  CAS  PubMed  Google Scholar 

  • Kamai T, Tsujii T, Arai K, Takagi K, Asami H, Ito Y et al. (2003b). Significant association of Rho/ROCK pathway with invasion and metastasis of bladder cancer. Clin Cancer Res 9: 2632–2641.

    CAS  PubMed  Google Scholar 

  • Kowalski TJ, Spar BD, Markowitz L, Maguire M, Golovko A, Yang S et al. (2005). Transgenic overexpression of neuromedin U promotes leanness and hypophagia in mice. J Endocrinol 185: 151–164.

    Article  CAS  PubMed  Google Scholar 

  • Martignoni ME, Kunze P, Friess H . (2003). Cancer cachexia. Mol Cancer 2: 36.

    Article  PubMed  PubMed Central  Google Scholar 

  • Moriyama M, Matsukawa A, Kudoh S, Takahashi T, Sato T, Kano T et al. (2006). The neuropeptide neuromedin U promotes IL-6 production from macrophages and endotoxin shock. Biochem Biophys Res Commun 341: 1149–1154.

    Article  CAS  PubMed  Google Scholar 

  • Moriyama M, Sato T, Inoue H, Fukuyama S, Teranishi H, Kangawa K et al. (2005). The neuropeptide neuromedin U promotes inflammation by direct activation of mast cells. J Exp Med 202: 217–224.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Nelson J, Bagnato A, Battistini B, Nisen P . (2003). The endothelin axis: emerging role in cancer. Nat Rev Cancer 3: 110–116.

    Article  CAS  PubMed  Google Scholar 

  • Oxford G, Theodorescu D . (2003). The role of Ras superfamily proteins in bladder cancer progression. J Urol 170: 1987–1993.

    Article  CAS  PubMed  Google Scholar 

  • Robinson VL, Kauffman EC, Sokoloff MH, Rinker-Schaeffer CW . (2004). The basic biology of metastasis. Cancer Treat Res 118: 1–21.

    Article  CAS  PubMed  Google Scholar 

  • Sahai E, Marshall CJ . (2002). RHO-GTPases and cancer. Nat Rev Cancer 2: 133–142.

    Article  PubMed  Google Scholar 

  • Seraj MJ, Harding MA, Gildea JJ, Welch DR, Theodorescu D . (2000). The relationship of BRMS1 and RhoGDI2 gene expression to metastatic potential in lineage related human bladder cancer cell lines. Clin Exp Metast 18: 519–525.

    Article  CAS  Google Scholar 

  • Shetzline SE, Rallapalli R, Dowd KJ, Zou S, Nakata Y, Swider CR et al. (2004). Neuromedin U: a Myb-regulated autocrine growth factor for human myeloid leukemias. Blood 104: 1833–1840.

    Article  CAS  PubMed  Google Scholar 

  • Shousha S, Nakahara K, Sato M, Mori K, Miyazato M, Kangawa K et al. (2006). Effect of neuromedin S on feeding regulation in the Japanese quail. Neurosci Lett 391: 87–90.

    Article  CAS  PubMed  Google Scholar 

  • Steeg PS . (2003). Metastasis suppressors alter the signal transduction of cancer cells. Nat Rev Cancer 3: 55–63.

    Article  CAS  PubMed  Google Scholar 

  • Strassmann G, Kambayashi T . (1995). Inhibition of experimental cancer cachexia by anti-cytokine and anti-cytokine-receptor therapy. Cytokines Mol Ther 1: 107–113.

    CAS  PubMed  Google Scholar 

  • Theodorescu D, Sapinoso LM, Conaway MR, Oxford G, Hampton GM, Frierson Jr HF . (2004). Reduced expression of metastasis suppressor RhoGDI2 is associated with decreased survival for patients with bladder cancer. Clin Cancer Res 10: 3800–3806.

    Article  CAS  PubMed  Google Scholar 

  • Tisdale MJ . (2005). Molecular pathways leading to cancer cachexia. Physiology (Bethesda) 20: 340–348.

    CAS  Google Scholar 

  • Titus B, Frierson Jr HF, Conaway M, Ching K, Guise T, Chirgwin J et al. (2005). Endothelin axis is a target of the lung metastasis suppressor gene RhoGDI2. Cancer Res 65: 7320–7327.

    Article  CAS  PubMed  Google Scholar 

  • Welch DR . (2004). Microarrays bring new insights into understanding of breast cancer metastasis to bone. Breast Cancer Res 6: 61–64.

    Article  CAS  PubMed  Google Scholar 

  • Yamashita K, Upadhyay S, Osada M, Hoque MO, Xiao Y, Mori M et al. (2002). Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell 2: 485–495.

    Article  CAS  PubMed  Google Scholar 

  • Yu XH, Cao CQ, Mennicken F, Puma C, Dray A, O’Donnell D et al. (2003). Pro-nociceptive effects of neuromedin U in rat. Neuroscience 120: 467–474.

    Article  CAS  PubMed  Google Scholar 

  • Zheng X, Hu Y, Liu J, Ouyang K . (2005). Screening of active compounds as neuromedin U2 receptor agonist from natural products. Bioorg Med Chem Lett 15: 4531–4535.

    Article  CAS  PubMed  Google Scholar 

  • Zhou X, Suto S, Ota T, Tatsuka M . (2004). Nuclear translocation of cleaved LyGDI dissociated from Rho and Rac during Trp53-dependent ionizing radiation-induced apoptosis of thymus cells in vitro. Radiat Res 162: 287–295.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by NIH Grant CA075115 to DT.

Author information

Authors and Affiliations

  1. Department of Molecular Physiology and Biological Physics, University of Virginia, Charlottesville, VA, USA

    Y Wu, K McRoberts & D Theodorescu

  2. Department of Radiology, University of Virginia, Charlottesville, VA, USA

    S S Berr

  3. Department of Pathology, University of Virginia, Charlottesville, VA, USA

    H F Frierson Jr

  4. Department of Heath Evaluation Sciences, University of Virginia, Charlottesville, VA, USA

    M Conaway

Authors
  1. Y Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K McRoberts
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S S Berr
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H F Frierson Jr
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M Conaway
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. D Theodorescu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D Theodorescu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wu, Y., McRoberts, K., Berr, S. et al. Neuromedin U is regulated by the metastasis suppressor RhoGDI2 and is a novel promoter of tumor formation, lung metastasis and cancer cachexia. Oncogene 26, 765–773 (2007). https://doi.org/10.1038/sj.onc.1209835

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1209835

Keywords

This article is cited by

Search

Advanced search

Quick links